[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"median-arcuate-ligament-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:median-arcuate-ligament-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100475258","coeliac-artery-release-or-sham-operation-100475258",false,"NCT05468580","Coeliac Artery Release or Sham Operation","Coeliac Artery Release or Sham Operation in Patients Suspected of the Median Arcuate Ligament Syndrome","CARoSO","Inclusion Criteria:\n\n* Patients with a consensus diagnosis of MALS based on a multidisciplinary discussion in the two Dutch expert centers for Mesenteric Ischemia (Medisch Spectrum Twente and Erasmus Medical Centre). The multidisciplinary team contains of a vascular surgeon, gastroenterologist, radiologist as recommended in the guidelines.\n* Typical complaints: post-prandial pain and at least two of the following: dietary modification, unexplained weight loss, unexplained diarrhea.\n* Eccentric stenosis of ≥70% of the AC at the medial arcuatum ligament, demonstrated by two imaging techniques (duplex, MRA, CTA or DSA), including at least an inspiration and expiration CTA with 1mm sections. (Definition percent stenosis according to ECST 1998 formula: % stenosis = (1 - \\[diameter at the site of stenosis\u002Festimated original diameter at the site of the stenosis\\]) x 100).\n* Ultrasound Abdomen without other more common abnormalities.\n* Gastroscopy-duodenoscopy without abnormalities, unless appropriate for mucosal ischemia.\n\nExclusion Criteria:\n\n* Patient not suitable for endoscopic AC release (e.g. previous surgery in the operating area).\n* Pregnancy.\n* Previous (endovascular) intervention of the visceral arteries.\n* A significant stenosis in the superior or in the inferior mesenteric artery.","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","In patients with Median Arcuate Ligament Syndrome (MALS), significant external compression of the coeliac artery (CA) by the median arcuate ligament (MAL) increasing mucosal ischemia (1,2) is assumed to cause chronic disabling postprandial abdominal pain, weight loss, and consequently lethargy and social deprivation (3,8). The majority of these patients have had a long medical journey before the diagnosis MALS is considered resulting in a substantial burden of disease and high healthcare and societal costs.\n\nAlthough a Systematic Review have shown a sustainable symptom relief of 68% and a significant and durable improvement of quality of life after surgical treatment for MALS (4), there is still no (inter)national consensus on the existence and treatment of MALS (1, 5, 6, 7).\n\nTwo recent guidelines (3, 8) concluded that patients with MALS might be considered for surgical CA release (Recommendation 25 GRADE 2D; expert agreement 96%, Terlouw 2020). To end the ongoing debate and to enable the development of evidence-based guidelines for the management of MALS, both guideline committees recommend to perform a blinded, randomised controlled trial comparing a CA release with a sham operation. The proposed Coeliac Artery Release or Sham Operation study will either underline the usefulness of eCAR as a minimal invasive (cost)effective treatment for MALS or it will prohibit a meaningless intervention in patients with disabling abdominal symptoms.\n\nIf the CARoSO study proves that the treatment of MALS by eCAR is effective, to 490 patients with chronic disabling abdominal symptoms per year can be treated in the Netherlands. Effective treatment of MALS is expected to result in mean health gain of 6.05 Quality Adjusted Life Years (QALYs)\u002Fpatient and has the potency to reduce the substantial productivity loss and healthcare consumption caused by MALS, resulting in a saving up to M€4.3\u002Fyear. The outcome of the CARoSO study will be translated into strong recommendations in the coming updates of the relevant (inter)national multidisciplinary guidelines and will be adapted in daily practice.",[27,28,29,30,31],"Mesenteric Ischemia","Median Arcuate Ligament Syndrome","Dunbar Syndrome","Coeliac Artery Compression","Celiac Artery Compression Syndrome",[33,34,35,36,37,38],"MALS","Mesenteric ischaemia","Quality of Life","Coeliac Artery Release","Sham Operation","Healthcare Costs","RECRUITING","2026-03-12",{"date":42,"type":43},"2026-03-16","ACTUAL",{"date":45,"type":43},"2023-04-01",{"date":47,"type":21},"2028-11-01",{"name":49,"class":50},"Medisch Spectrum Twente","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":51},"100552106","intestinal-ischemia-biomarker-in-patients-with-chronic-mesenteric-ischemia-100552106","NCT06468774","Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia","Intestinal Ischemia Biomarker and Quality of Life of the Patients With Chronic Mesenteric Ischemia and Median Arcuate Ligament Syndrome","Inclusion Criteria: Above 18 years and has given informed written consent for treatment and study participation\n\nFor the patient groups :\n\nGroup 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment.\n\nGroup 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment.\n\nFor the control group:\n\nGroup 3- Has ultrasound based diagnosis of cholelithiasis and is scheduled for cholecystectomy.\n\nGroup 4- Has established Mb Crohn diagnosis and under gastric lab follow-up. Group 5- Young healthy blood donors of mean age 45 years and has excluded MALS or CMi with ultrasound.\n\nGroup 6- Healthy blood donors of mean age 70 years and has excluded MALS or CMi with ultrasound.\n\nExclusion Criteria: Age less than 18 years Has nor given written consent.\n\n\\-",true,{"count":61,"type":21},180,"OBSERVATIONAL","Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals.\n\nThis study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals.\n\nBesides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.",[65,28,66,67],"Chronic Mesenteric Ischemia","Crohn Disease","Cholelithiasis",[69,70,33,71],"Intestinal ishchemia biomarker","alpha GST","Chronic mesenteric ischemia","2025-07-29",{"date":74,"type":43},"2025-07-30",{"date":76,"type":43},"2024-06-10",{"date":78,"type":21},"2037-05-31",{"name":80,"class":50},"Oslo University Hospital"]